Five talking points from England's win over Portugal
Hampton's footwork can help her be No 1
The week leading up to the Nations League win over Portugal was dominated by the news of Mary Earps's retirement from international football 39 days before the European champions begin their title defence. The supremely talented Hannah Hampton had slowly moved into pole position for the starting spot in Switzerland, with Sarina Wiegman having said the Chelsea keeper was a little ahead of Earps, the Euro 2022 and 2023 World Cup No 1. Hampton has performed well when given the chance to start, but how she will cope with the pressure of being first choice long-term? Portugal were perfect opponents to ease her way in, England's utter domination in the 6-0 win leaving her very little to do. Spain will offer a far greater test on Tuesday but Hampton, whose distribution is superior, was preferred to Earps against the world champions in February.
Returning heroes show their worth
The sight of Lauren Hemp in the starting XI against Portugal was welcome. As was that of Alex Greenwood and Georgia Stanway, who were on the bench, coming on. All three have been in a race against time to be fit for the Euros and they showed what England has been missing this year. Hemp was electric on the left and her teammate Grace Clinton said: 'Out of possession, in possession, she's an unbelievable player. She's got one-v-one, she's got dribbling, she's got pace with her runs in behind, she's got everything.' Wiegman said: 'It's really nice to see them back. They have worked so hard to get to where they are … if you haven't put all the work into getting to this point then you cannot put in the performance they showed tonight.
Wiegman shows her ruthless streak
Wiegman is a winner and she wanted a big victory against Portugal, a team England have struggled against having drawn 1-1 in the reverse fixture in February and held to a 0-0 draw in a friendly on the eve of the 2023 World Cup. Aggie Beever-Jones said: 'As cliched as it sounds, Sarina said: 'It's a new kit, new England today. Go out there and put a graft in.' I think her words were 'destroy them', in her Dutch accent.' That edge and hunger to win aren't always positive, Wiegman's reaction to Earps's retirement reportedly having been a very angry one, but when it comes to putting together winning formulas on the pitch there are few better managers.
Steps forward up front
England have had limited attacking options since Euro 2022, with Beth Mead injuring an anterior cruciate ligament and Lauren James more recently having hamstring problems, while Chloe Kelly was frozen out at Manchester City in the first half of this season. However, things seem to be coming together at the right time: Mead is looking closer to her best, she and Kelly – after a loan move – are Champions League winners with Arsenal and Hemp is well and truly back. Throw in the youngsters Beever-Jones, who scored a hat-trick against Portugal, and Michelle Agyemang, who scored 41 seconds into her debut against Belgium last month, and the forward choices look strong. 'We have so many options,' said Wiegman. 'What we also hope for is LJ [Lauren James] coming back too. She's still in rehab and doing good.'
Medal winners bring a boost
Wiegman said the five Arsenal Champions League winners had brought energy to the England camp. 'They were so happy. It was absolutely brilliant they won it. I just get goosebumps thinking about it. It's incredible and they came in that way too. They got a little bit longer break to celebrate and it was very enjoyable with them.' Kelly, Mead, Leah Williamson, Lotte Wubben-Moy and Alessia Russo weren't the only ones with shiny new medals: add in Chelsea's unbeaten treble-winners and Jess Carter, who won the Concacaf Champions Cup with Gotham FC last Sunday, and England are stacked with domestic and continental victors.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Montemurro appointed new Australia women's football coach
Joe Montemurro has been appointed head coach of the Australian women's team (JUSTIN TALLIS) Joe Montemurro was appointed head coach of the Australia women's team Monday, returning home after a successful decade in Europe with Arsenal, Juventus and Lyon. The 55-year-old, who steered French powerhouses Lyon to their fourth consecutive women's league title last month, said it was "the honour of a lifetime". Advertisement "This team means so much to so many Australians, and I'm humbled by the opportunity to help shape its next chapter," he said. "I've followed their incredible journey closely and am energised by the passion, resilience, and identity they've built." The Matildas captivated the nation and won legions of new fans with their run to the last four of the World Cup on home soil in 2023. But an underwhelming Paris Olympics last year saw Tony Gustavsson depart and they have been without a permanent head coach since. Tom Sermanni, a 70-year-old Scot, has been in temporary charge during a protracted recruitment process, with the side sliding to 16th in the world. Advertisement "Joe brings world-class experience, a deep understanding of the Australian football landscape, and a genuine connection to our national identity," said Football Australia interim chief Heather Garriock. "Importantly, he has spent the last decade coaching at the very highest levels of the women's game in Europe and brings with him an unparalleled understanding of what is required to compete and succeed at the top of modern football." Montemurro, who won trophies with women's teams at Lyon, Juventus, Arsenal and Melbourne City, will lead the Matildas to the Asian Cup on home soil next year, then through qualifying for the 2027 Women's World Cup. mp/dh
Yahoo
36 minutes ago
- Yahoo
Pharmacists warn drug shortage affecting cancer patients
Pharmacists have warned that "one of the worst" examples of medicine shortages is affecting cancer patients. Creon, a pancreatic enzyme replacement therapy (Pert), helps digestion and is required by patients with pancreatic cancer, cystic fibrosis, and chronic pancreatitis. It is thought more than 61,000 patients in the UK need the medicine. Some patients are said to be "skipping meals" to ration their medication due to a shortage of it, according to the National Pharmacy Association (NPA). A Department of Health and Social Care spokesperson said there were "European-wide supply issues" and it was "working closely with industry and the NHS" to mitigate the impact on patients. Without the drug, patients lose weight and strength, which means their ability to cope with treatment such as chemotherapy is reduced. Some experts have predicted shortages continuing until next year. The Department of Health and Social Care has extended a serious shortage protocol for Creon which has already been in place for a year. This indicates concern about shortages of a medicine and allows pharmacists to give patients an alternative - though they argue other drugs are also in short supply. A spokesperson for the department said the "European-wide supply issues" were caused by manufacturing supply constraints. The National Pharmacy Association said more than three quarters of members covered in a recent survey felt the current arrangements for managing the shortages were inadequate. Some reported that patients were skipping meals and travelling long distances to get hold of the medication, according to the NPA. One said it was the "worst stock shortage" they had ever had to deal with. BBC News highlighted the issue in February after a woman got in touch saying it was impossible for her husband, who has pancreatic cancer, to digest his food without Creon. That month, leading pancreatic clinicians and charities wrote to the prime minister, saying the absence of Pert can have a "devastating impact on people's lives". They called for a national strategy to tackle the shortage. Alice from Birmingham was diagnosed with pancreatic cancer in 2023 and initially got 15 boxes of Creon capsules every month to help her tolerate chemotherapy. She can now get only six or seven and is having to skip snacks. The 64-year-old said the shortage had profoundly affected her mental health. She told the BBC: "Each day I'm trying to balance: what shall I eat, shall I have a more substantial meal, shall I take my supplements and that creates an extra layer of stress and worry whilst I'm trying to put my life together again after having this diagnosis." Alfie Bailey-Bearfield of Pancreatic Cancer UK said the charity had been raising concerns with the government and suppliers for more than a year and it was vital that officials intervened to try to boost supply. "Thousands of people affected by pancreatic cancer rely on taking Pert tablets every time they eat simply to digest their food and absorb nutrients – something most of us take for granted," he said. "It's totally unacceptable that they are still taking desperate measures which puts their health, wellbeing and their eligibility for treatment at risk," he added. Dr Leyla Hannbeck, chief executive of the Independent Pharmacies Association said it was very difficult for her members to obtain supplies from the wholesaler. "The shortages with Creon has been ongoing for so long and it seems no effective attempts are being made by officials to make the process easier for pharmacies and patients and to put robust plans in place to prioritise the availability of this product," she said. "Instead they continue prolonging the current processes." A Department of Health and Social Care spokesperson said it knew "how frustrating and distressing" medicine supply issues can be for patients and clinicians caring for them. They added: "The European-wide supply issues with Creon are caused by a limited availability of raw ingredients and manufacturing capacity constraints. "We are working closely with industry and the NHS to mitigate the impact on patients and resolve the issues as quickly as possible." Cancer patients 'may starve' without vital drug
Yahoo
an hour ago
- Yahoo
Asia share markets, dollar wary on tariff news
By Wayne Cole SYDNEY (Reuters) - Asian share markets made a wary start to the week on Monday as investors navigated the shifting sands of White House tariff policy, while awaiting key U.S. jobs data and a widely expected cut in European interest rates. There was little obvious reaction to President Donald Trump's threat late Friday to double tariffs on imported steel and aluminium to 50%, beginning on June 4, a sudden twist that drew the ire of European Union negotiators. Speaking on Sunday, Treasury Secretary Scott Bessent said Trump would soon speak with Chinese President Xi Jinping to iron out a dispute over critical minerals. White House officials continued to play down a court ruling that Trump had overstepped his authority by imposing across-the-board duties on imports from U.S. trading partners. "The court ruling will complicate the path ahead on trade policy, but there remains an ample set of provisions available to the administration to deliver its desired results," said Bruce Kasman, chief economist at JPMorgan. "There is a commitment to maintaining a minimum U.S. tariff rate of at least 10% and imposing further sector tariff increases," he added. "An increase in ASEAN to discourage transhipment looks likely, and the bias for higher tariffs on US-EU trade persists." Markets will be particularly interested to see if Trump goes ahead with the 50% tariff on Wednesday, or backs off as he has done so often before. In the meantime, caution reigned and MSCI's broadest index of Asia-Pacific shares outside Japan went flat. Japan's Nikkei fell 1.1%, while South Korean stocks dipped 0.1%. S&P 500 futures eased 0.2% and Nasdaq futures lost 0.3%. The S&P climbed 6.2% in May, while the Nasdaq rallied 9.6% on hopes final import levies will be far lower than the initial sky-high levels. Front-running the tariffs has already caused wild swings in the economy, with a contraction in the first quarter likely turning into a jump this quarter as imports fall back. The Atlanta Fed GDPNow estimate is running at an annualised 3.8%, though analysts assume this will slow sharply in the second half of the year. Data this week on U.S. manufacturing and jobs will offer a timely reading on the pulse of activity, with payrolls seen rising 130,000 in May while unemployment stays at 4.2%. EYEING UNEMPLOYMENT A rise in unemployment is one of the few developments that could get the Federal Reserve to start thinking of easing policy again, with investors having largely given up on a cut this month or next. A move in September is seen at around a 75% chance, though Fed officials have stopped well short of endorsing such pricing. There are at least 11 Fed speakers on the diary for this week, led by Fed Chair Jerome Powell later on Monday. Fed Governor Christopher Waller did say on Sunday that cuts remain possible later this year as he saw downside risks to economic activity and employment and upside risks to inflation from the tariffs. A softer jobs report would be a relief for the Treasury market, where 30-year yields continue to flirt with the 5% barrier as investors demand a higher premium to offset the ever-expanding supply of debt. The Senate this week will start considering a tax-and-spending bill that will add an estimated $3.8 trillion to the federal government's $36.2 trillion in debt. Across the Atlantic, the European Central Bank is considered almost certain to cut its rates by a quarter point to 2.0% on Thursday, while markets will be sensitive to guidance on the chance of another move as early as July. The Bank of Canada meets Wednesday and markets imply a 76% chance it will hold rates at 2.75%, while sounding dovish on the future given the tariff-fuelled risk of recession there. Widening rate spreads have so far offered only limited support to the U.S. dollar. "The greenback remains near the lower end of its post-2022 range and considerably weaker than interest rate differentials would imply," noted Jonas Goltermann, deputy chief markets economist at Capital Economics. "Sentiment around the greenback remains negative and it continues to look vulnerable to further bad news on the fiscal and trade policy fronts." On Monday, the dollar had dipped 0.2% on the yen to 143.79, while the euro edged up a fraction to $1.1353. [USD/] The greenback also slipped 0.1% on the Canadian dollar to 1.3727, getting no tailwind from Trump's threat of 50% tariffs on Canadian steel exports. In commodity markets, gold edged up 0.6% to $3,310 an ounce, having lost 1.9% last week. [GOL/] Oil prices bounced after OPEC+ decided to increase output in July by the same amount as it did in each of the prior two months, a relief to some who had feared an even bigger increase. [O/R] Brent rose $1.07 to $63.85 a barrel, while U.S. crude gained $1.18 to $61.95 per barrel. Sign in to access your portfolio
